Skip to main content
28/10/2026

Two Vall d'Hebron professionals awarded at the ICS Research Awards 2026

Premis de Recerca de l'ICS 2026

ICS Research Awards 2026

28/10/2026

Dr. Natalia Mendoza and Dr. Manuel Analís Bernal have received the Young Researcher and the Best Research Article by a Resident Awards, respectively.

On October 28, the Catalan Health Institute (ICS) held its 17th Research Conference, including the presentation of the ICS Research Awards. In this edition, two professionals from the Vall d'Hebron Research Institute (VHIR) have been awarded.

Young Researcher Award

Dr. Natalia Mendoza, physician in the Pediatric Infectious Diseases and Immunodeficiencies Unit at Vall d’Hebron University Hospital and principal investigator of the Infection and Immunity in Pediatric Patients group at VHIR, received the Young Researcher Award. The recognition highlights her contribution to advancing health sciences research within the ICS through work of acknowledged scientific excellence.

Dr. Mendoza’s career is distinguished by a combination of scientific excellence, emerging leadership and clinical impact. Her research focuses on antimicrobial stewardship and infections in oncohematology and transplant patients, with particular interest in the development of antimicrobial stewardship (ASP/PROA) programmes in paediatrics, emerging mycoses, new antifungal therapies in children, and improved management of febrile neutropenia.

She has participated as a principal investigator or collaborator in national and international competitive research projects and has coordinated two national clinical practice guidelines. She also co-leads the Young Persons Advisory Group (YPAG-KIDS Vall d’Hebron), which promotes the active participation of children and adolescents in research.

In 2017, Dr Mendoza was awarded an Amics del VHIR predoctoral fellowship, made possible thanks to the financial contributions of the Amics de Vall d’Hebron.

Best Research Article by a Resident Award

Furthermore, Dr. Manuel Alanís Bernal, a resident in the Neurology Department at Vall d’Hebron University Hospital and a researcher in the Status Epilepticus and Acute Seizures Research Group at VHIR, has been awarded the Best Research Article by a Resident Award for his research entitled “Long-term mortality after status epilepticus: A 5-year analysis study”.

The study, published in the journal Epilepsia, analyses long-term mortality following an episode of status epilepticus. Based on a cohort of 786 patients, the five-year mortality rate was found to reach 50.3%, with almost half of the deaths occurring within the first two years. Several factors independently associated with higher mortality were identified, including advanced age, pre-existing disability, comorbidities, and systemic complications. Furthermore, the study confirms the long-term prognostic value of the Lattanzi etiological classification and the ACD scale. These findings contribute to a better understanding of the prognosis of status epilepticus and may help identify patients at higher risk and optimise their follow-up.

The 17th ICS Research Conference

This year’s 17th ICS Research Conference was devoted to chronicity and healthy ageing, with the aim of sharing advances and research lines being developed across the ICS ecosystem and its research institutes. The event brought together healthcare professionals and researchers to exchange evidence, projects and innovative experiences, while reflecting on the current and future challenges of an increasingly ageing population.

Among other topics, the conference included a roundtable discussion on chronicity research moderated by Dr. Rafael Simó, head of the Diabetes and Metabolism Group at VHIR, with the participation of Dr. Meritxell Bellet, medical oncologist at the Medical Oncology Department of Vall d’Hebron University Hospital and researcher in the Breast Cancer group at the Vall d’Hebron Institute of Oncology (VHIO).

Related news

The Hub will lead a clinical study to evaluate a remote blood-sampling device in the paediatric population, in line with the objectives of the BRIDGE project to facilitate access to clinical trials for all children.

The appointments were announced at the society congress, where seven studies from Vall d’Hebron were also presented.

The vaccine activates both antibody production and the T-cell response, maintaining, for at least one year, a higher immune response than before vaccination.

Related professionals

Natalia Ana Mendoza Palomar

Natalia Ana Mendoza Palomar

Main researcher
Infection and immunity in pediatric patients
Read more
Manuel Alanis Bernal

Manuel Alanis Bernal

Main researcher
Research Group on Status Epilepticus and Acute Seizures
Read more
Lorena Almerich Diego

Lorena Almerich Diego

Research technician
Research Group on Status Epilepticus and Acute Seizures
Read more
Estevo Santamarina Pérez

Estevo Santamarina Pérez

Head of group
Research Group on Status Epilepticus and Acute Seizures
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.